CSO Bill Lund­berg tran­si­tions to ad­vi­sor role at CRISPR Ther­a­peu­tics; Prothena los­es CMO Sarah Noon­berg; Sanofi vet Mark Nut­tall jumps to Kymera

→ Wrap­ping a three-year run marked by the first clin­i­cal tri­al ap­pli­ca­tions for CRISPR-based ther­a­pies, Bill Lund­berg is step­ping down as CSO of CRISPR Ther­a­peu­tics $CR­SP. He will stay with the com­pa­ny as the head of its sci­en­tif­ic ad­vi­so­ry board. This con­tin­ues a pe­ri­od of tran­si­tion af­ter Sam Kulka­rni took over from found­ing CEO Rodger No­vak in Oc­to­ber. Much of the sci­en­tif­ic lead­er­ship now falls up­on Tony Ho, head of R&D.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER